Souhaitez-vous accéder aux communiqués récents ?

EXTON, PA, June 12, 2025 (GLOBE NEWSWIRE) -- As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on the cusp of significant evolution...

EXTON, PA, June 10, 2025 (GLOBE NEWSWIRE) -- Patients battling focal segmental glomerulosclerosis (FSGS) often face a discouraging path, marked by continued disease progression and limited...

EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent...

EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is...

EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for generalized myasthenia gravis (gMG) has entered a new era of therapeutic innovation. Since 2022, seven novel targeted...

EXTON, PA, May 13, 2025 (GLOBE NEWSWIRE) -- Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights from Spherix Global...

EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA...

EXTON, PA, May 01, 2025 (GLOBE NEWSWIRE) -- Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks....

EXTON, PA, April 30, 2025 (GLOBE NEWSWIRE) -- The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis (LN) have led specialists to reconsider their...

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable...